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Abstract 
Background 
Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially 
reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by 
intense renal arterial vasoconstriction, it carries a very poor prognosis. There is a significant 
unmet need for a widely approved, safe and effective pharmacological treatment. 
 
Aim  
To re-evaluate efficacy and safety of pharmacological treatments for HRS1, in light of recently 
published randomised controlled trials (RCTs). 
 
Methods  
MEDLINE(OvidSP), EMBASE, PubMed and Cochrane registers were searched for RCTs 
reporting efficacy and adverse events related to pharmacological treatment of HRS1. Search 
terms included: ‘hepatorenal syndrome’, ‘terlipressin’, ‘noradrenaline’, ‘octreotide’, 
‘midodrine’, ‘vasopressin’, ‘dopamine’, ‘albumin’ and synonyms. Comparison of vasoactive 
drugs versus placebo/no treatment, and two active drugs were included. Meta-analysis was 
performed for HRS1 reversal, creatinine improvement, mortality and adverse events.  
 
Results  
12 RCTs enrolling 700 HRS1 patients were included. Treatment with terlipressin and albumin 
led to HRS1 reversal more frequently than albumin alone or placebo (RR:2.54,95%CI:1.51-
4.26). Noradrenaline was effective in reversing HRS1, but trials were small and non-blinded. 
Overall, there was mortality benefit with terlipressin (RR:0.79,95%CI:0.63-1.01), but 
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sensitivity analysis including only trials with low risk of selection bias weakened this 
relationship (RR:0.87,95%CI:0.71-1.06). Notably, there was a significant risk of adverse events 
with terlipressin therapy (RR4.32,95%CI:0.75-24.86).  
 
Conclusion 
Terlipressin treatment is superior to placebo for achieving HRS1 reversal, but mortality 
benefit is less clear. Terlipressin is associated with significant adverse events, but infusion 
regimens may be better tolerated. There is continued need for safe and effective treatment 
options for hepatorenal syndrome.   
 
 
 
 
 
 
 
 
 
 
 
 
  
 4 
Introduction 
 
Hepatorenal syndrome (HRS) is a severe form of acute kidney injury (AKI) that typically occurs 
in patients with decompensated liver cirrhosis, but is also a frequent complication of 
fulminant hepatic failure and acute alcoholic hepatitis. HRS remains a diagnosis of exclusion1 
and is associated with a dismal prognosis.2 With an estimated annual incidence in the United 
States of 9,000–14,000 patients, HRS is present in approximately 15% of patients admitted to 
hospital with ascites and develops in more than 50% of cirrhotics who die.3 
Clinically there are two distinct types of HRS. Type-1 HRS (HRS1) is characterized by rapidly 
progressive kidney failure, which is most frequently precipitated by acute bacterial infection 
and a dysregulated systemic inflammatory response. If left untreated, HRS1 has a 2-week 
mortality rate of ~80%.4 In contrast, renal impairment in type-2 HRS (HRS2) is slower in onset 
and progression and typically occurs in patients with refractory ascites. The median survival 
of HRS2 is around 6 months without liver transplantation.4  
Intense renal arterial vasoconstriction is thought to be the central mechanism underlying the 
functional renal failure that characterizes HRS.5 In cirrhosis, HRS occurs in response to portal 
hypertension and splanchnic arterial vasodilatation that results in a reduction in effective 
circulating volume. The development of a hyperdynamic circulation and activation of 
homeostatic neurohormonal mechanisms (such as the renin-angiotensin-aldosterone system, 
vasopressin and the sympathetic nervous system) maintain arterial blood pressure via 
increased cardiac output and heart rate, heightened systemic vascular tone, and sodium and 
water retention, but also causes renal vasoconstriction.6 Pooling of blood in the splanchnic 
circulation also alters gut permeability and enhances bacterial translocation, with the release 
of endotoxin and increase in pro-inflammatory cytokines leading to amplification of 
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circulatory dysfunction.7 As cirrhosis and splanchnic vasodilation progress, cardiac output is 
no longer able to compensate and systemic hypotension occurs.6  The combination of 
hypotension and peripheral vasoconstriction leads to reduced tissue perfusion in extra-
splanchnic organs including the kidneys and brain.8 This ‘splanchnic steal phenomenon’ 
leaves patients vulnerable to episodes of non-HRS AKI, HRS and hepatic encephalopathy. HRS 
develops when renal blood flow falls below the level required to maintain glomerular 
filtration rate.  
The optimum treatment for HRS is liver transplantation, but this is limited by donor 
availability and patients often die before transplantation can occur. Interestingly, renal artery 
resistive indices can take up to a year to return to normal following transplant9 and recovery 
of renal function is not universal.10 Indeed, complete recovery of kidney function only 
occurred in 58% of patients within 4-110 days of liver transplantation, 15% partially 
recovered, and 25% never recovered.10 Effective pharmacological therapy for HRS1 is 
therefore an important requirement. Evidence suggests that HRS1 is potentially reversible if 
haemodynamic derangements are corrected in a timely fashion. However, if uncorrected, 
prolonged renal arteriolar vasoconstriction and parenchymal ischaemia may result in acute 
tubular necrosis.11 Vasoconstrictor drugs and albumin infusion currently form the mainstay 
of treatment for HRS1. Such vasoconstrictors induce systemic and splanchnic 
vasoconstriction, thereby increasing systolic blood pressure and augmenting effective arterial 
blood volume. In theory, increased renal perfusion follows as systolic blood pressure rises and 
neurohormonal systems are attenuated. Three classes of vasoconstrictor have been studied 
in HRS1.  Vasopressin analogues such as ornipressin and terlipressin act upon vasopressin-1 
receptors on the vascular smooth muscle causing vasoconstriction. Additionally, these drugs 
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reduce portal pressure. Terlipressin is used in many countries for the treatment of HRS1 but 
it is not approved by the Food and Drug Administration for use in the USA and Canada. 
Noradrenaline and midodrine are -adrenergic agonists that similarly lead to constriction of 
vascular smooth muscle and increase systemic vascular resistance. Midodrine is often used in 
combination with octreotide, a somatostatin analogue that inhibits the release of systemic 
vasodilators such as glucagon.  
Many previous studies evaluating the efficacy and safety of these agents were small, 
uncontrolled, non-blinded and poorly designed. In the last decade several randomised 
controlled trials (RCTs) have been published with varying conclusions. Some of these trials 
combined patients with HRS1 and HRS2 despite significant differences in the severity, rate of 
progression, and prognosis of these conditions.  More recently a number of appropriately 
powered, well-designed RCTs in patients with HRS1 alone have been reported.  
In light of recent advancements in the literature, the aim of this systematic review and meta-
analysis was to re-evaluate the efficacy and safety of available pharmacological treatments 
for HRS1. 
 
Methods 
Study design 
This systematic review and meta-analysis was registered in the PROSPERO international 
prospective register of systematic reviews (CRD42016042921) and reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).12 
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Search strategy and study selection 
An electronic search was performed through to June 2016 using MEDLINE(OvidSP), EMBASE, 
PubMed and both the Cochrane Central Register of Controlled Trials, and the Cochrane 
Hepatobiliary Group Register. Manual searches of selected speciality journals and conference 
proceedings (Appendix 1, Supplementary material (Supp Material)) were performed to 
identify all pertinent literature. Similarly, reference lists from published clinical trials and 
previous systematic reviews were examined. Our search was limited to human studies that 
were published in English. No date limitation was applied. 
Search terms included ‘hepatorenal syndrome’, ‘terlipressin’, ‘noradrenaline’, ‘octreotide’, 
‘midodrine’, ‘vasopressin’, ‘dopamine’, ‘albumin’ and their synonyms. Studies deemed 
eligible for inclusion were RCTs in adults (18 years) with HRS1 as defined by the International 
Ascites Club in 2007.13 Comparisons between two pharmacological agents, or one active drug 
and placebo/no treatment were included. Moreover, papers were excluded if they did not 
report one or more of the outcomes of interest, as outlined in Table 1. One investigator (FJG) 
performed an initial review of all titles in order to exclude duplicates and non-relevant 
literature. Two investigators (JAF and FJG) then independently judged eligibility of all 
abstracts. A third investigator (JRM) reviewed a subset (10%) of studies to check the accuracy 
of selection and data extraction, and to resolve any disagreements that emerged.  
Data extraction and study quality assessment 
Two investigators (JAF and FJG) independently extracted data using a standardised data 
collection form in Microsoft Excel version 15.20. Extracted data included patient 
characteristics, treatment arm, comparator groups, and selected outcomes. Additionally, 
country of origin, single or multi-centre status, randomisation and blinding procedures, 
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funding source, duration of follow-up, number of patient withdrawals, and appropriate 
powering of the study were noted. Where possible, data was extracted as intention-to-treat 
analyses.  
The quality of included studies was appraised using the Cochrane Collaboration’s tool for 
assessing the risk of bias.14 Risk of bias was judged as low, high or unclear within seven 
domains: sequence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, missing outcome data, selective reporting and 
other sources of bias. 
Study outcomes and statistical analysis 
Outcomes of interest included HRS1 reversal (as defined by each individual trial), improved 
serum creatinine (sCr), and all–cause mortality. Additionally, data was recorded on adverse 
events, focussing specifically on ischaemic adverse events. The relative risk (RR) and 95% 
confidence intervals (95% CI) were calculated for each outcome. Meta-analysis was 
performed using a Mantel-Haenszel random-effects model in view of the expected 
heterogeneity between trials (varying inclusion criteria, treatment dose, duration and 
definition of outcomes). The heterogeneity between studies was quantified using the I2 
statistic with I2 <25% representing low heterogeneity, 25-50% moderate and >50% I2 high 
inter-trial heterogeneity. Each therapeutic method was analysed separately. A sensitivity 
analysis of treatment effect was undertaken using only trials judged as having low risk of 
selection bias on the grounds of sequence generation and allocation concealment.15 All 
analyses were performed using REVMAN version 5.3 (Nordic Cochrane Centre, Copenhagen, 
Denmark). 
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Results 
Study characteristics and risk of bias 
The literature search identified a total of 2739 manuscripts. 894 papers were duplicates, and 
1629 citations were removed after screening of titles.  A further 169 publications were 
excluded after abstract review, leaving 24 full text articles. 12 studies were excluded: 6 as 
after contacting the primary authors for further information only an abstract was available; 2 
were not RCTs; 3 did not separate HRS1 and HRS2 patients when reporting their results; and 
one further study (Hadengue et al, 1998)16 was later excluded due to insufficient outcome 
reporting.  
A total of 12 papers were included in the final analysis (Figure 1).17-28 All included studies were 
RCTs. Treatment comparisons included terlipressin, noradrenaline, octreotide and midodrine, 
low dose dopamine, and placebo. All trials used albumin or a similar plasma expander in both 
treatment and comparator groups. Four studies included both HRS1 and HRS2 patients, but 
reported results for the HRS1 subgroup independently.19,26-28 Study characteristics are shown 
in Table 2.  
A total of 700 participants with HRS1 were included in our series. Mean age was 53 years, and 
participants were 74% male (Silawat et al23 did not publish the age or sex of their 
participants). Overall treatment time varied between 5 and 19 days, with a mean of 14 days. 
Average albumin dose was 12.5–40g/day. In two multi-centre studies, concomitant albumin 
use was recommended but not universally applied.17,21 Four studies allowed paracentesis for 
tense ascites when required.22,25,26,28 Two of these stated that additional albumin therapy was 
given during paracentesis.22,28 Length of follow-up varied between 15 and 180 days. 5 studies 
(45%) had 90-day follow up (Table 2). Silawat et al23 did not define length of follow-up.  
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In studies examining the use of terlipressin, the initial terlipressin dose varied from 1mg/day 
to 6mg/day. 6 of the 10 studies increased the terlipressin dose on day 3-5 if only a partial 
response was seen.17-19,21,22,24 The maximum dose of terlipressin was 8-12mg/day. Neri et al20 
routinely reduced terlipressin dose on day 5 from 3mg/day to 1.5mg/day. In studies using 
noradrenaline, the dose was recorded as 0.5-3mg/hour22,24 or 0.1-0.7g/kg/min.27,28  
Bias 
17% studies had high risk of bias for allocation concealment, 83% for blinding of participants 
and 58% for blinding of outcome assessment. Two trials were double-blinded (18%).17,21 One 
was reported to be single-blinded, however it did not state if the blinding referred to the 
patient or investigator.25 9 studies (75%) were non-blinded, although one open-label study 
reported that outcome assessors were blinded.26 25% of included studies were judged to have 
a high risk of bias due to incomplete outcome data and a further 8% for selective reporting. 
58% of trials published a sample size calculation. Boyer et al amended the recruitment target 
mid-trial, then continued to recruit until 30 patients had achieved complete HRS1 reversal.17 
The trial by Martin-Llahi et al was terminated early after interim analysis revealed an 
unexpectedly low event rate.19 Similarly, the study by Srivastava et al was deemed to be 
significantly underpowered,26 although sample size calculations are not included in the risk of 
bias domains defined by Cochrane.14 The paper by Silawat et al had a high risk of bias in 5 of 
7 domains.23 Sensitivity analysis was subsequently performed incorporating only low risk 
trials. Assessment of Cochrane risk of bias is outlined in Table 3. 
 
Results of data analysis by comparison: 
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The definition of HRS1 reversal varied across studies and for two trials the diagnostic criteria 
was not specified.23,25 Only two studies used the existing gold standard definition of ‘two sCr 
measurements of ≤ 132µmol/L on 2 occasions, at least 48 hours apart without death, renal 
replacement therapy or HRS1 recurrence’.17,21 For the purpose of meta-analysis, the 
definition of HRS1 reversal was taken as a sCr ≤ 132µmol/L on at least one occasion. 
11 of the 12 included trials reported mortality data for HRS1 patients. Martin-Llahi et al did 
not sub-divide mortality data by HRS1 and HRS2 and therefore this study was not included in 
this analysis.19  
Reporting of adverse events was also variable between studies. Frequently listed complaints 
included abdominal pain/presumed intestinal ischaemia, myocardial infarction, arrhythmias, 
electrocardiogram (ECG) changes and digital ischaemia. The study by Alessandria et al was 
unclear with regard to adverse event rates, stating that ‘most’ patients treated with 
terlipressin experienced transient abdominal cramps and watery diarrhoea. Consequently, 
adverse event data from this study was included in the meta-analysis for ischaemic adverse 
events only.28 
 
Terlipressin + albumin vs no intervention/placebo + albumin 
Terlipressin plus albumin significantly increased the chance that a patient would achieve HRS1 
reversal (RR 2.54, 95% CI 1.51 to 4.26; I2 52%; Figure 2) compared to albumin alone, or with 
placebo. A similar, but more modest result was obtained when the analysis was restricted to 
papers with low risk of selection bias (RR 2.11, 95% CI 1.28 to 3.49; I2 40%; Analysis 1.3 Supp 
Material). Three studies provided additional information on patients who showed a partial 
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response to vasoconstrictor therapy (drop by >50% from baseline sCr).18-20 Analysis of all 
patients with improved sCr favoured the use of terlipressin versus placebo (RR: 1.66, 95% CI 
1.07 to 2.57, Figure 2).  
 
Terlipressin reduced the risk of mortality when compared with placebo/no intervention (RR: 
0.79, 95% CI 0.63 to 1.01, I2 53%, Analysis 1.1 Supp Material). However sub-group analysis 
including only papers with low risk of selection bias weakened this relationship with a RR of 
0.87 (95% CI 0.71 to 1.06, Analysis 1.2 Supp Material). Repeat meta-analysis after omitting 
the trial by Solanki et al (low risk of selection bias but high risk of detection bias) revealed a 
RR of 0.93 (95% CI 0.80 to 1.09).  
 
The use of terlipressin significantly increased the risk of all adverse events when compared to 
placebo (RR 4.32, 95% CI 0.75 to 24.86, Figure 3). Further analysis showed the RR of an 
ischaemic adverse event whilst using terlipressin to be 3.56 (95% CI 1.64 to 7.72) compared 
to placebo. 
 
Terlipressin infusion vs terlipressin bolus  
Cavallin et al compared terlipressin infusion with bolus therapy and showed that HRS1 
reversal was more likely with terlipressin infusion (RR: 1.22, 95% CI 0.77 to 1.93, Analysis 2.1 
Supp Material).18 Moreover, terlipressin infusion led to greater sCr improvement (RR: 1.18, 
95% CI 0.87 to 1.59, Analysis 2.2 Supp Material), reduced the risk of all adverse events (RR 
0.48, 95% CI 0.22 to 1.01, Analysis 2.4 Supp Material), and specifically ischaemic adverse 
events (RR 0.63, 95% CI 0.28 to 1.42) compared with bolus therapy. Despite this, infusion of 
 13 
terlipressin was inferior to bolus therapy with respect to mortality rate (RR: 1.58, 95% CI 0.86 
to 2.91, Analysis 2.3 Supp Material). 
 
Terlipressin + albumin vs noradrenaline + albumin 
Terlipressin and noradrenaline treatment performed equally with regard to HRS1 reversal 
(RR: 0.99, 95% CI 0.67 to 1.45, Analysis 3.1 Supp Material). However, mortality rate with 
terlipressin was marginally worse compared with noradrenaline (RR: 1.04, 95% CI 0.74 to 1.47, 
Analysis 3.2 Supp Material). The use of terlipressin significantly increased the risk of all 
adverse events when compared with noradrenaline (RR: 2.14, 95% CI 0.81 to 5.69, Analysis 
3.3 Supp Material). However, terlipressin induced fewer ischaemic adverse events than 
noradrenaline, although numbers were small (RR: 0.63, 95% CI 0.15 to 2.59). 
 
Terlipressin + albumin vs dopamine + standard care  
For HRS1 reversal, the evaluation of terlipressin versus low dose dopamine favoured 
terlipressin (RR 2.00, 95% CI 1.14 to 3.52, Analysis 4.1 Supp Material).  However, in this 
comparison terlipressin treatment did not show a significant survival benefit (RR: 0.98, 95% 
CI 0.76 to 1.26, Analysis 4.2 Supp Material), although participant numbers were small. 
Terlipressin significantly increased the risk of all adverse events (RR 4.79, 95% CI 0.46 to 49.60, 
Analysis 4.3 Supp Material) and ischaemic adverse events (RR:2.18, 95% CI 0.51 to 9.34) when 
compared with low dose dopamine.  
Noradrenaline + albumin vs Octreotide, Midodrine + albumin 
 14 
Noradrenaline performed better than midodrine and octreotide for achieving HRS1 reversal 
(RR: 1.25, 95% CI 0.70 to 2.24, Analysis 5.1 Supp Material), but was found to be inferior in 
reducing mortality (RR: 1.50, 95% CI 0.60 to 3.78, Analysis 5.2 Supp Material). No adverse 
events were reported for either treatment in this study.  
 
Discussion 
HRS1 is a rapidly fatal disease if left untreated. Until recently, a significant proportion of the 
literature consisted of poorly designed, non-blinded studies with incomplete outcome 
reporting. Additionally, some studies had pooled both HRS1 and HRS2 patients together.  
Given the significant disparity in speed of onset and progression, severity, and outcomes 
related to these two conditions, we believe that they should be considered separately. 
Recently, larger well designed and appropriately powered RCTs have shed further light on this 
important area.17,18 A prior systematic review (Cochrane 2012)29 reported that treatment with 
terlipressin alone or in combination with albumin achieved reversal of HRS1 more frequently 
than albumin alone (RR: 3.76, 95% CI 2.21 to 6.39). Moreover, terlipressin reduced mortality 
in patients with HRS1, compared to no intervention or placebo ± albumin (RR: 0.75, 95% CI 
0.59 to 0.97).  This relationship was maintained when studies with low risk of selection bias 
were analysed.  Our present review concords that terlipressin is more effective than albumin, 
alone or with placebo, for achieving HRS1 reversal. Furthermore, a similar reduction in 
mortality rate was seen with terlipressin in meta-analysis of all studies (RR:0.79, 95% CI 0.63 
to 1.01). However, when the analysis was repeated including only trials with low risk of 
selection bias this relationship weakened (RR: 0.87, 95% CI 0.71 to 1.06). In keeping with 
previous studies, we identified a significant risk of adverse events (RR 4.32, 95% CI 0.75 to 
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24.86), especially ischaemic adverse events (RR: 3.56, 95% CI 1.64 to 7.72) with terlipressin 
treatment. Indeed, terlipressin caused more serious adverse events than any other 
vasoconstrictor. Prior to study recruitment, potential participants were screened for 
significant cardiovascular risk factors, so this may in fact be an under-estimate of the true 
population risk. Recording of adverse events was unreliable in several studies, with possible 
reporting bias and the suggestion that low adverse event rates were related to lower doses 
of terlipressin.  
Pooled data comparing terlipressin and noradrenaline showed no evidence of superiority of 
terlipressin over noradrenaline for achieving HRS1 reversal (RR: 0.99, 95% CI 0.67 to 1.45. 
Terlipressin appeared marginally inferior to noradrenaline with regard to mortality (RR: 1.04, 
95% CI 0.74 to 1.47). Notably, the confidence intervals for both of these results crossed 1, so 
the validity of this data is uncertain. Furthermore, the three trials comparing noradrenaline 
and terlipressin were small, non-blinded, single centre studies.22,24,28 Meta-analysis suggested 
fewer ischaemic adverse events with noradrenaline, although patient numbers were small 
and confidence intervals broad. Noradrenaline was superior to octreotide and midodrine with 
respect to HRS1 reversal, but not survival or adverse event rate. 
Interestingly, Matto et al recently compared both the efficacy and cost of terlipressin and 
noradrenaline therapy.30 Their study reinforced previous literature concluding that neither 
vasoconstrictor was superior with respect to HRS1 reversal or 30-day mortality. However, 
unlike other economic analyses where only the cost of the vasoconstrictor drug was 
considered, Matto et al calculated all direct medical costs involved in a hypothetical 
hospitalisation using each of the studied medications. These calculations included the costs 
accrued in the intensive care unit, where a patient must be monitored if noradrenaline is 
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infused. This economic evaluation is arguably a more accurate assessment of real-world costs, 
and suggested that terlipressin is a more cost-effective treatment than noradrenaline.  
Additionally, Salerno et al recently published a meta-analysis of 19 studies (8 RCTs, 8 
prospective and 3 retrospective studies) suggesting a dose-response relationship between 
albumin therapy and survival in HRS1 patients.31 As cumulative albumin dose increased in 
100g increments, survival improved significantly (hazard ratio (HR) 1.15, CI: 1.02-1.31, 
p=0.02). A similar relationship was shown for reversal of HRS1, however these results did not 
reach statistical significance (HR: 1.15, CI: 0.97-1.37, p=0.10). Although the included studies 
were not powered to demonstrate a relationship between albumin dose and outcomes, this 
meta-analysis highlights its potential importance.  
Despite restricting our analysis to only HRS1 patients, and performing repeat analysis of low 
risk trials, there remain some limitations to this review. The overall sample size was small and 
many studies had inadequate blinding and did not report sample size calculations. Moreover, 
true HRS1 is a relatively infrequent diagnosis, even in large tertiary referral centres. This is 
evidenced by the three most recent multi-centre studies where Boyer et al recruited 196 
patients from 52 sites over 2.5 years, Cavallin et al recruited 78 patients from 3 centres over 
7 years, and Sanyal et al recruited 112 patients from 35 centres over 2.5 years. In stark 
contrast to this, Silawat et al recruited 60 HRS1 patients from a single centre in 6 months. This 
disparity suggests that strict diagnostic criteria may not have been adhered to. Indeed, some 
patients labelled as HRS1 were reported to have “refractory ascites”, which is more typically 
associated with HRS2. This may, in part, explain the variation seen in historical meta-analyses 
of vasoconstrictor therapies for HRS. The use of stringent criteria for study inclusion and the 
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addition of recent high quality studies, may arguably render the results of our updated meta-
analysis more reliable.  
A recent meta-analysis by Belcher et al suggested that improvement in sCr, when taken as a 
continuous variable, was a valid surrogate marker for mortality.32 This implies that even 
partial improvement in sCr may lead to improved short-term survival. Importantly, some 
patients now survive long enough to undergo liver transplantation. Furthermore, as pre-
transplant renal dysfunction is associated with increased morbidity and mortality after liver 
transplantation, any increase in renal function (whether complete or partial HRS reversal) 
may improve outcomes.33 In contrast, survival in HRS1 ‘non-responders’ is extremely low.34  
In view of the severity of this condition and limitations of currently available drug therapy, 
the Food and Drug Administration recently granted HRS orphan disease status in an attempt 
to accelerate the development of more effective treatments.   
An ideal treatment for HRS1 would theoretically consist of a drug with selective vasodilator 
activity in the renal circulation but without significant vasodilator effects in other vascular 
beds, especially the splanchnic circulation. However, nitrates may have potentially 
deleterious effects on renal function in cirrhosis.35 Fenoldopam, a selective dopamine-1 
receptor agonist with renoprotective properties, has been evaluated in patients with post-
operative AKI36 but randomized placebo-controlled studies in cirrhosis are lacking. Other 
investigational agents such as the thromboxane receptor antagonist ifetrobam 
(ClinicalTrials.gov: NCT01436500) and the relaxin family peptide receptor-1 agonist serelaxin 
(ClinicalTrials.gov: NCT01640964) are in clinical development and may have therapeutic 
potential for the treatment of portal hypertension and/or renal dysfunction in cirrhosis.  
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Figure legends 
 
 
Table 1. Eligibility criteria 
Table 1. USS; ultrasound, sCr; serum creatinine, TIPS; transjugular intrahepatic portosystemic shunt, HRS; 
hepatorenal syndrome. 
 
 
Table 2. Study characteristics 
 
 
Table 3. Risk of bias summary: review authors' judgements about each risk of bias item for 
each included study. 
Risk of bias: Green; low risk of bias, Red; high risk of bias, Orange; unclear risk of bias 
1. Insufficient information provided. 2. Non-blinded. 3. Trial terminated after preliminary analysis.                     
4. Randomisation chart used- possibility for selection bias. 5. Outcome data incomplete. 6. Primary outcome 
not defined or reported. 7. Missing detail: duration of treatment/follow up, possibility of lenient inclusion 
criteria. 8. Single blinded. 
 
 
Figure 1. Flow chat of study selection 
 
 
Figure 2. Terlipressin +/- albumin vs no intervention/placebo +/- albumin.  
Outcomes: HRS reversal and improved sCr 
 
 
Figure 3. Terlipressin +/- albumin vs no intervention/placebo +/- albumin.  
Outcome: Adverse events 
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Table 1 
 
 
- Randomised, controlled trials 
- Published in English 
- Adults (18 years) 
- Type 1 hepatorenal syndrome: 
 Liver cirrhosis (clinical, biochemical, USS, biopsy, or endoscopy diagnosis) 
 sCr >133mol/L (>1.5mg/dL) 
 No improvement in sCr after 2 days diuretic withdrawal + volume expansion 
 Absence of shock (doctor defined) 
 No current or recent nephrotoxin use 
 No macroscopic signs of structural kidney injury (urine dipstick/USS)  
- Excluding patients with previous TIPS or liver transplant 
- Outcomes include one or more of the following: 
 HRS reversal (as defined by individual author) 
 Improved renal function 
 Mortality 
 All serious adverse events 
 Cardiovascular adverse events 
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Table 2 
 
 Single/Multi-centre Treatment 1 Dose Treatment 2 Dose Treatment 
duration 
Length of 
follow up 
Alessandria 
(2007) 
Single 
(Italy) 
Terlipressin + albumin 
(n = 5) 
1-2mg/4h Noradrenaline + albumin 
(n = 4) 
0.1-0.7g/kg/min 14 days 180 days 
Boyer 
(2016) 
Multi  
(USA/Canada) 
Terlipressin + albumin 
(n = 97) 
1-2mg/6h Placebo + albumin 
(n = 99) 
N/A 14 days 90 days 
Cavallin 
(2015) 
Multi  
(Italy) 
Terlipressin infusion  
+ albumin (n = 34) 
2-12mg/day Terlipressin bolus + albumin  
(n = 37) 
0.5-2mg/4h 15 days 90 days 
Martin-Llahi 
(2008) 
Multi  
(Spain) 
Terlipressin + albumin 
(n = 17) 
1-2mg/4h Albumin alone 
(n = 18) 
N/A 15 days 90 days 
Neri  
(2008) 
Single  
(Italy) 
Terlipressin + albumin 
(n = 26) 
1mg/8h (5days) then 
0.5mg/8h (14 days) 
Albumin alone 
(n = 26) 
N/A 19 days 90 days 
Sanyal 
(2008) 
Multi 
(USA/Germany/Russia) 
Terlipressin + albumin 
(n = 56) 
1-2mg/6h Placebo + albumin 
(n = 56) 
N/A 14 days 180 days 
Sharma 
(2008) 
Single  
(India) 
Terlipressin + albumin 
(n = 20)  
0.5-2mg/6h Noradrenaline + albumin 
(n = 20) 
0.5-3mg/h 15 days 15 days 
Silawat 
(2011) 
Single  
(Pakistan) 
Terlipressin + albumin 
(n = 30) 
0.5-1mg/12h Low dose dopamine + plasma 
expanders (n = 30) 
4g/min Not stated Not stated 
Singh  
(2012) 
Single  
(India) 
Terlipressin + albumin 
(n = 23) 
0.5-2mg/6h Noradrenaline + albumin 
(n = 23) 
0.5-3mg/h 15 days 30 days 
Solanki 
(2003) 
Single  
(India) 
Terlipressin + albumin 
(n = 12) 
1mg/12h Placebo + albumin 
(n = 12) 
N/A 15 days 15 days 
Srivastava 
(2015) 
Single  
(India) 
Terlipressin + albumin 
(n = 20) 
0.5mg/6h Low dose dopamine, 
furosemide + albumin (n = 20) 
2g/kg/min 5 days 30 days 
Tavakkoli 
(2012) 
Single  
(Iran) 
Noradrenaline + 
albumin (n = 6) 
0.1-0.7g/kg/min Octreotide, Midodrine + 
albumin (n = 9) 
100-200g/8h 
5-15mg/8h 
15 days 90 days 
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Table 3 
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Figure 1 
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Figure 2 
 
 
HRS reversal 
 
 
Improved sCr
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Figure 3 
 
All adverse events 
 
Ischaemic adverse events 
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Supplementary material 
 
1. Terlipressin +/- albumin vs no intervention/placebo +/- albumin 
 
1.1 All studies - Mortality 
 
 
 
 
 
Low risk of selection bias based on the assessment of allocation methods (sequence 
generation and allocation concealment)  
 
 
1.2 Low risk studies – Mortality 
 
 
 
 
1.3 Low risk studies - HRS reversal (sCr<132micromol/L) 
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1.4 Low risk studies - Adverse events 
 
All adverse events 
 
 
 
Ischaemic adverse events 
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Supplementary material 
 
2. Terlipressin infusion vs terlipressin bolus (Forest plot of comparison)     
2.1 HRS reversal (sCr<132micromol/L) 
 
2.2 Improved serum creatinine      
 
 
 
 
2.3 Mortality  
 
 
 
 
2.4 Adverse events 
 
All adverse events 
 
 
Ischaemic adverse events 
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Supplementary material 
 
3. Terlipressin vs Noradrenaline (Forest plot of comparison)     
 
3.1 HRS reversal (sCr<132micromol/L)  
 
 
 
 
3.2 Mortality 
 
 
 
3.3 Adverse events 
 
All adverse events 
 
 
 
 
 
Ischaemic adverse events 
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Supplementary material 
 
4. Terlipressin + albumin vs Dopamine + standard care (Forest plot of comparison)     
 
4.1 HRS reversal (sCr<132micromol/L) 
 
 
 
 
4.2 Mortality 
 
 
 
 
4.3 Adverse events 
 
All adverse events 
 
 
 
Ischaemic adverse events 
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Supplementary material 
 
5. Noradrenaline + albumin vs Octreotide + Midodrine + albumin (Forest plot of 
comparison 
 
5.1 HRS reversal (sCr<132micromol/L) 
 
 
 
 
5.2 Mortality 
 
 
 
 
5.3 Adverse events 
 
All adverse events 
 
 
 
 
Ischaemic adverse events 
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Supplementary material 
 
Appendix 1 
 
List of speciality journals included in manual search for additional pertinent literature 
 
1. Journal of Hepatology 
2. Gastroenterology 
3. Journal of Gastroenterology and Hepatology 
4. American Journal of Gastroenterology 
5. Hepatology 
6. European Journal of Gastroenterology and Hepatology 
7. Alimentary, Pharmacology and Therapeutics 
8. Liver International 
9. Digestive Diseases and Sciences 
10. Nephrology Dialysis Transplantation 
11. GUT 
12. Nature Reviews Gastroenterology and Hepatology 
 
 
 
Conference proceedings 
 
1. AASLD: American Association for the Study of Liver Diseases (Hepatology) 
2. EASL: European Association for the Study of the Liver (Journal of Hepatology) 
3. ERA-EDTA: European Renal Association- European Dialysis and Transplant Association 
(Nephrology Dialysis Transplantation) 
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Section/topic  # Checklist item  
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on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4-6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
7 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
6-7 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
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Table 1 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
7 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
7-8 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
7-8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
8 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
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Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
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10-13, 
Supp 
material 
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Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Supp 
material 
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Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  10-13 
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